Navigation Links
Heart Disease: An Epidemic For Firefighters
Date:3/17/2009

Landmark FEMA Study Results Released

ATLANTA, March 17 /PRNewswire/ -- H. Robert Superko, MD, principal investigator in the landmark FEMA-sponsored study of firefighters aged 40 and over conducted at Saint Joseph's Hospital in Atlanta, released preliminary findings in the world's first study of first responders at risk of suffering sudden death or other significant cardiac events. Firefighters are known to have a three hundred percent increased risk for cardiac disease as compared to other segments of the population.

"Preliminary findings show that one third of firefighters had heart disease that is unrelated to traditional risk factors, such as high cholesterol," says Dr. Superko. "Those results are astounding and point at job duties and environment as the primary determinants for early death in our country's first responders."

Dr. Superko, recognized as a leading expert on lipids, cholesterol and advanced metabolic markets and their contribution to heart disease, and his team performed a comprehensive, scientific battery of sophisticated blood and imaging tests on three hundred firefighters in Gwinnett County, Georgia. Gwinnett County first responders were identified for the study following an emotional report by Fire Chief Steve Rolader, following the sudden death of one of his firefighters from cardiac arrest while fighting a house fire.

"This wasn't the first firefighter in my department to die but I wanted to do something to make it among the last," says Chief Rolader. "This man was 53 years old, in great physical shape and he had no known symptoms of heart disease. We also had lost several newly-retired firefighters to sudden cardiac death. There had to be a way to stop it."

Study volunteers underwent a comprehensive genetic screen of more than a million genes including newly identified KIF6 (statin responsiveness gene) and 9p21 (myocardial
'/>"/>

SOURCE Saint Joseph's Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
4. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
5. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
8. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
9. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE ... financial results will be released on Thursday, August 13, ... Eastern Time, Pfenex management will host a conference call ... update.  A press release outlining the financial results and ... call. Please call 1-866-376-8058 (US) or 1-412-542-4131 ...
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... 18 CV Therapeutics,Inc. (Nasdaq: CVTX ) ... (FDA) has approved new language for the product ... ability,of ranolazine to inhibit the late sodium current ... mechanism suggests that during ischemic,episodes excess sodium can ...
... (NYSE: DGX ), the nation,s leading provider ... its Board of,Directors declared a quarterly cash dividend ... payable on January 23, 2008, to shareholders of,record ... Quest Diagnostics is the leading provider of ...
... Ore., Dec. 18 Synthetech, Inc. (OTC,Bulletin ... Performance Improvement,Awards for their outstanding accomplishments in ... Silver Awards are presented by,the Synthetic Organic ... SOCMA,s EHS&S initiative. The awards are highly,regarded ...
Cached Biology Technology:FDA Approves New Mechanism of Action Labeling for Ranexa(R) 2Quest Diagnostics Declares Quarterly Cash Dividend 2Synthetech Earns National Recognition for Performance Improvement Program 2Synthetech Earns National Recognition for Performance Improvement Program 3
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/26/2015)... -- ATL Technology, LLC, a top provider of electromechanical contract ... solutions, headquartered in Springville, Utah , has ... corporation with locations in Santa Clara, ... ). This acquisition will incorporate MedConx,s manufacturing ... Technology,s existing facility in Costa Rica , ...
(Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... of Community Health (MDCH) has unveiled the state,s ... significant recommendations developed from medical research conducted by ... Kennedy Shriver National Institute for Child Health and ... the Wayne State University School of Medicine. ...
... bottles from the drugstore the human body makes ... University have found a way to use naturally occurring ... Their method also serves as a highly sensitive hydrogen ... role in cellular health and disease. In a ...
... have known for some time that throwing off the ... fact, workers whose sleep-wake cycles are disrupted by night ... as diabetes, obesity and cancer. Researchers at the ... possible molecular link between circadian rhythm disturbances and an ...
Cached Biology News:State of Michigan adopts NIH's PRB progesterone therapy to combat infant mortality 2State of Michigan adopts NIH's PRB progesterone therapy to combat infant mortality 3Scientists discover molecular link between circadian clock disturbances and inflammatory diseases 2Scientists discover molecular link between circadian clock disturbances and inflammatory diseases 3
... Choice Microsphere/Microarray Stabilizer is a is a ... This product is an aqueous solution ... buffer (phosphate buffered saline), pH 6.6 - ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
... F1 antigen, Monoclonal Antibody, Unconjugated ... Use at an assay dependent dilution. ... dilution. WB: Use at an assay ... kDa. Not tested in other applications. ...
... formulated for mounting tissue specimens, cell smears, ... immunohistochemical methods for viewing by light microscopy. ... such as AEC, that are alcohol-soluble or ... when slides are cover-slipped forming a coating ...
... is formulated for covering tissue sections and cell preparations immunohistochemically ... products. , ... Application: Vision ... AEC that require an aqueous mounting medium, or those that ...
Biology Products: